FMS - Where Will Cara Therapeutics Be in 5 Years?
It's hard to forecast exactly how a specific stock will perform over just a 12-month period, let alone over five years. This is especially true for smaller biotech stocks, where there's an even greater degree of uncertainty due to the nature of the drug candidate development process.
Cara Therapeutics (NASDAQ: CARA) is one of the more promising biotech stocks on the market due to its leading drug candidate, a kidney disease-related pruritus drug known as Korsuva. However, there's a bit of uncertainty regarding the treatment, especially in light of some mixed clinical trial results.
Let's take a deeper look at Korsuva's results, what this means for Cara Therapeutics, and where the company could go in the next few years.